"Failure of this trial to reach its primary efficacy endpoint has forced me (and everybody else) to rethink this issue. Much more clinical and preclinical research is needed before we can define the role of renal denervation in the management of hypertension and its complications/comorbidities.Suzanne Oparil, MD, University of Alabama at Birmingham.
